The management of cataract in glaucoma patients has been continuously changing over the past decade. Extracapsular cataract extraction has been replaced by small-incision phacoemulsification with foldable lenses, and in glaucoma surgery, adjunctive antifibrotic therapy based on risk factors for failure has become standard. Furthermore, new techniques in filtering and nonfiltering surgery have been suggested. The techniques, however, change so fast that well-controlled studies with a follow-up of more than 12 months are increasingly seldom. The purpose of this paper is to review the current literature and to point out some new ideas for the future investigation.
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Sequential or combined surgery
There is constant discussion about the handling of cases with coexisting cataract and glaucoma. Many surgeons prefer a primary cataract extraction and then to observe the glaucoma. No doubt, a cataract extraction can lower the intraocular pressure (IOP) in eyes with glaucoma [1] . If the cataract extraction does not reduce the IOP to an acceptable level, trabeculectomy can be performed at a later stage. The drawback of this approach is that IOPspikes can appear in the early postoperative period (ie, first 24 hours) even after quite uneventful cataract extractions. This was first noted by Rich et al. [2] , and has been confirmed by others [3] [4] [5] . These early IOP spikes probably will do no harm to normal eyes, but pose a potential threat in glaucomatous eyes.
Indications for sequential surgery Primary phacoemulsification followed later by trabeculectomy
If visual impairment caused by cataract is the main problem, and the IOP is well controlled, phaco is recommended.
In a prospective, randomized, controlled study, Gimbel et al. [6] evaluated the IOP reduction in patients whose eyes had ocular hypertension and primary open angle glaucoma who had either combined phaco-trab or only phaco. After 2 years, the IOP reduction in the group who had combined therapy was 6.1 mm Hg and 3.8 mm Hg in the group of control subjects; however, Gimbel et al. did not addressed the question of early postoperative IOPspikes. Hopkins et al. [7] and investigated phaco-trab versus phaco procedures in patients with cataract and primary open angle glaucoma with special reference to early IOP spikes (less than 24 hours), and they both found that the combined procedure reduced the frequency and the magnitude of early IOP spikes, although they could not be eliminated.
If visual function is threatened because IOP is not well controlled, or only controlled with heavy medication, and the cataract is a minor problem, trabeculectomy would be a natural choice, followed by a cataract extraction 3 to 6 months later without any hazard to the trabeculectomy. Park et al. [9] demonstrated this in a retrospective, casecontrolled study evaluating the effect of temporal phaco on IOP in eyes that had prior trabeculectomy, and they found no adverse effect on long-term IOP control. Costa et al. [10] and Park et al. [11] compared IOP control in patients who had coexisting cataract and glaucoma and who had either phaco-trab, or trabeculectomy alone. These authors concluded that trabeculectomy alone was associated with better long-term reduction of IOP.
5-FU

Indication for combined procedure
The surgical indication for a combined procedure is visually significant cataract and glaucoma on maximum acceptable medication, with the need of safeguarding against IOP spike-related optic nerve damage during the early postoperative period [12] . The indication can be extended to include patients with poor compliance or patients exhibiting contraindication to medication because of allergy or cardiopulmonary disease [8] . Another consideration is the obvious advantage of patient comfort and economy in a combined procedure, instead of two separate operations.
Small-incision phacoemulsification and antiproliferative agents have altered the approach to combined surgery. Several studies comparing extracapsular cataract extraction-trabeculectomy (ECCE-trab) to phacoemulsification-trabeculectomy (phaco-trab) have shown that the phaco-trab is superior to ECCE-trab because of faster visual rehabilitation [13, 14] , better long-term IOP control [13] [14] [15] , less medication [13] [14] [15] , less postoperative inflammation [13, 15] , and fewer complications, like choroidal detachment and hypotony [15] . The results of several large-scale cohort series with phaco-trab have been published, and they all show phaco-trab to be a safe procedure with excellent long-term IOP control and visual outcome [16] [17] [18] .
Surgical techniques in combined procedures
Many techniques have been proposed to solve the conflicting problem of a watertight cataract incision and a patent filtering glaucoma procedure. Cataract surgeons prefer cataract incisions to be watertight to minimize hypotension, shallow chambers, and the risk of intraocular infections. On the other hand, glaucoma surgeons intend to make a fistulation through the incision to create a patent filtering bleb. Performing the combined procedure involves the conflicting problem of combining a watertight cataract incision with a patent filtering glaucoma procedure.
One-site approach versus two-site approach
Wyse et al. [19] reported on a series of 33 eyes of 33 patients who had cataracts or glaucoma and who were randomly assigned to undergo either a one-site or twosite combined procedure. After a follow-up period of 16 months, corrected visual acuity improved and IOP decreased in both groups without significant difference. The main difference was that the group who had the one-site procedure required significantly more medica-tion to maintain IOP control than did the group who had the two-site procedure.
El-Sayyad et al.
[20] carried out a prospective, randomized study on 76 eyes that had coexisting cataract and glaucoma, comparing the use of one-site and two-site phaco-trab with adjunctive mitomycin C. At last followup, the patients who underwent one-site phaco-trabs required more medication to control IOP. Clinically apparent filtering blebs were noted in 39 % in the group who had the one-site procedure, compared with 59% in the group who underwent the two-site procedure. Borggrefe et al.
[21•] conducted a prospective, randomized comparison of the one-site and two-site approaches. These authors found IOP reduction to be more pronounced in the group who had had the two-site procedure, but the difference was not significant.
Shared incision versus two separate incisions in the one-site approach
Nielsen [22] carried out a prospective, nonrandomized study on 36 eyes in 26 patients who had coexisting cataract and glaucoma and who had phaco-trab. In 10 eyes, the operation was done through the same incision, and in the other 26 eyes, the cataract incision was separated from the trabeculectomy incision, still during the onesite approach. Nielsen did not found any statistical difference after 1 year regarding IOP control, astigmatism, or visual acuity between the two groups. The patients whose eyes had had two incisions needed fewer medication and had a better filtering bleb than those who had had one incision, but the difference was not statistically significant.
Gimbel et al.
[23•] reported a series of 83 eyes in 77 patients who had phaco combined with viscocanalostomy. The study was retrospective and non-randomized with a observational period of 6 months. In 46 eyes, the phaco and viscocanalostomy was made using the same incision, and in the other 37 eyes, the operation was carried out using two incisions. There was no difference in IOP control or complication between the two groups.
Fornix-based versus limbus-based conjunctival flap
It is still on debate as to whether to use a fornix-based or a limbus-based conjunctival incision. Two retrospective, nonrandomized studies in patients undergoing combined trabeculectomy and phaco showed no difference in IOP control or visual acuity when either fornix-based or limbus-based conjunctival incisions were used [24, 25] .
In a prospective, fellow eye study in patients undergoing the combined procedure (patients, n = 44; eyes, n = 88) Shingleton et al. [26•] found no difference in IOP reduction or improving visual acuity between fornix-or limbus-based flap orientation. Lemon et al. [27] conducted a prospective, randomized study on two groups of patients (69 eyes in 69 patients): one group had the limbus-based conjunctival incision (n = 30 eyes), and the other group had the fornix-based conjunctival incision (n = 39 eyes). After 18 months, there was no difference between the groups in postoperative mean IOP, mean number of medicin, and visual acuity. Hypotony with wound leak was significantly more frequent in the group who had had the limbus-based conjunctival incision (P = 0.019).
Antimetabolites
Antimetabolites have been used in combination with filtering surgery to improve surgical results for more than 10 years. Clinical use of antimetabilites is, at the moment, clinically dominated by 5-fluorouracil (5-FU) and mitomycin C (MMC). Both drugs act by inhibiting of proliferation of fibroblasts and probably also affect cell migration and extracellular matrix production. Mietz [28] , and Loon and Chew [29] , have published excellent reviews of the toxicology of MMC and 5-FU. Three major reviews have given a thorough examination of wound healing [30], postsurgical hypotony [31], and dysfunctional filtering blebs [32] .
In short, the functional bleb shows subconjunctival flow and contains microcysts in the subepithelial connective tissue. Most often, the elevated, large, thin, avascular filtering blebs are associated with better IOP-control than are low blebs with thick, vascularized walls [29, 31] .
5-fluorouracil
Although 5-FU has proved its use in trabeculectomies [33] , the results when used in phaco-trab are not quite clear [34, 35] . O'Grady et al.
[34] prospectively investigated the effectiveness of 5-FU in primary trabeculectomy combined with phaco (one-site and one-insicion). Seventy-four patients were enrolled and randomly assigned into two groups that received either no 5-FU or low-dose 5-FU postoperatively (mean, 25 mg). At final control after 13 to 15 months, there was no difference in mean IOP, visual acuity or reduction in medication between the two groups.
Gandolfi and Vecchi [35] conducted a prospective, randomized, controlled trial to test the use of 5-FU in combined phaco-trab (a two-site technique was used in all cases). There were 12 eyes (12 patients) in the 5-FU group and 12 eyes (12 patients) in the control group. Diurnal IOP curves were measured 1, 3, 6, 9, and 12 months after surgery. At all controls IOP was significantly lower in the group that had 5-FU.
5-fluorouracil versus mitomycin C
Katz et al.
[36] carried out a randomized, clinical trial comparing the use of postoperative subconjunctival injection of 5-FU with a single intraoperative application of MMC in patients with high-risk eyes. Follow-up lasted more than 2 years. Eyes treated with MMC had lower IOP, using fewer medication, than did eyes treated with 5-FU. Late postoperative complications were similar with exception of Tenon cyst formation in the group who received MMC.
Mitomycin C
The usefulness of intraoperative, adjunctive MMC has been investigated in two prospective studies. Cohen et al.
[37] conducted a placebo-controlled, double-masked evaluation of MMC in combined procedures. Seventytwo eyes (of 72 patients) were randomly assigned to either MMC or placebo (n = 72 eyes). At 12 months, the group who received MMC experienced significantly greater IOP reduction, required less medication, and had significantly larger filtering blebs than the group who received a placebo. However, wound leaks were more common in the group who received MMC.
Carlson et al.
[38] also investigated the efficacy of intraoperative MMC in means of lower postoperative IOP and less medication. Of the patients enrolled in the study (total eyes, n = 29), some underwent phaco-trab without MMC (n = 15 eyes) and some underwent phacotrab with MMC (n = 14 eyes). Follow-up period was a mean of 20 months. The results showed that the group who received MMC had significantly lower postoperative IOP and required less medication than the group who underwent phaco-trab alone.
Risk of failure caused by scarring
Making the surgical decision for a filtering operation (with or without a cataract extraction) involves an estimation of prognostic risk factors for filtration failure. Some factors have been found significant for lack of success in this operation: black race; young age (less than 60 years); preoperative IOP greater than or equal to 20 mm Hg. Further, patients are at higher risk if they: are on two or more medications previous to surgery; have had medications for more than 3 years before surgery (especially epinephrine or epinephrine analogs); have aphakia or pseudophakia; have had previous glaucoma surgery that was unsuccessful; have chronic uveitis or neovascular glaucoma, or have undergone concomitant intraocular procedures such as vitrectomy [39-42,43•] .
Mitomycin C is a very potent antimetabolite, and a better understanding of the prognostic factors involved in its use is crucial. Shin et al. [39, 41, 42, 44] have carried out some very interesting studies on MMC and risk factors.
In a prospective, randomized study with a follow-up of 21 months, Shin et al.
[44] evaluated the potential benefit of MMC in patients who underwent combined surgery. Adjunctive MMC did not improve the final IOP reduction in patients who did not have risk factors for filtration failure.
In a following study, Shin et al. [39] tried to determine the prognostic factors for failure of surgery in patients with primary open angle glaucoma who underwent a combined procedure either with or without adjunctive MMC. They concluded that there was no statistical difference in the overall outcome of combined operation between the patients who had surgery and who received MMC, and the control group of nonselected patients. The factors mentioned earlier were identified to have a significant independent influence on failure without adjunctive MMC, but not with adjunctive MMC. Shin et al. proposed that the use of MMC may have to be restricted to patients having one or more of the prognostic factors for filtration failure.
In another clinical trial, Shin et al. [41] investigated the effect of MMC in patients both with and without prognostic factors for lack of success of filtration. One hundred ninety-seven patients (n = 197 eyes) were randomly assigned to either phaco-trab with no MMC (n = 101 eyes) or with adjunctive MMC (n = 96 eyes). These authors' findings established the basis for selective use of MMC in patients with primary open angle glaucoma who undergo the combined procedure.
Finally, Shin et al.
[42] also investigated whether previously failed trabeculectomy was a risk factor for lack of success of filtration in a subsequent phaco-trab, and they tried to determine the role of adjunctive MMC. They concluded that a previously unsuccessful filtering operation was a significant risk factor for the lack of success of filtration in the combined procedure. The intraoperative use of MMC significantly improved the filtration success rate of secondary phaco-trab, compared with the success rate of primary phaco-trab.
A dose-response effect seems to exist between concentration of MMC and postoperative IOP [45, 46] . Robin et al.
[47] performed a prospective, double-masked, placebo-controlled study evaluating the decrease in IOP in 300 patients (300 eyes) and found a possible doseresponse relationship between both concentration and duration of exposure to MMC. Length of exposure seemed to be more important than concentration. This stands in contradiction to the work of Cheung et al. [48] , who found no relation between the concentration of MMC, exposure time, and the lack of success of surgery. However, neither the distribution of concentration nor the exposure time of MMC were randomized in the study population.
The future
New ideas could involve the combination of phaco and new variations of filtering procedure. The next few years will clarify the potential benefit of these new filtering, nonpenetrating procedures.
Phaco combined with deep sclerectomy
In a prospective, randomized clinical trial, André Mermoud et al. [49••] combined phaco with deep sclerectomy and compared this new technique with standard phaco-trabs. With a follow-up period of 12 months, the deep sclerectomy showed similar good results as the phaco-trabs regarding visual outcome and IOP control, but with a lower complication rate.
Phaco combined with endoscopic laser cycloablation
Gayton et al.
[50•] combined phaco and endoscopic laser cycloablation. In a prospective study, 58 eyes of 58 patients were assigned randomly to either standard phacotrab or phaco plus endoscopic laser cycloablation (total eyes, n = 58; eyes in each group, n = 29). After 2 years follow-up, there was no statistical difference between the two groups concerning IOP reduction, number of medication, or visual outcome.
Phaco combined with viscocanalostomy
[23•] reported on patients who underwent phaco and viscocanalostomy (total eyes, n = 83). A shared scleral incision was made in 46 eyes, and a clear corneal incision separate from the viscocanalostomy, in 37 eyes. In a retrospective review of the cases, these authors found the procedure to be safe and efficacious in IOP reduction, whether or not a one-site or a two-site approach was used.
Wound-healing modification in filtering surgery
Peng Khaw et al. [51•] worked with the modulation of the wound-healing response, using monoclonal antibodies to human growth factors. This new approach to modulate the scarring process is an exciting therapeutic strategy, but we have only short clinical experience of it.
Conclusions
The combined procedure seems to be safe with a fast visual rehabilitation and a acceptable long-term IOP reduction on less postoperative medication. The complication rate is similar to sequential surgery with the advantage of better patient care, comfort, and economy [10, 11] . With current knowledge, a good option seems to be phacoemulsification through a clear corneal temporal incision, combined with a trabeculectomy at the position 11 1999, 25:340-346 . The Lusanne group with André Mermoud has published several papers concerning the efficacy and safety of deep sclerectomy (the Stegmann procedure). In this prospective, randomized study involving 60 eyes in 60 patients, 30 eyes had phaco-trab and 30 eyes had phaco-deep sclerectomy. The was no difference in IOP reduction or visual acuity between the two groups at any follow-up up to 18 months.
• 50 Gayton JL, Karr MVD, Sanders V: Combined cataract and glaucoma surgery: trabeculectomy versus endoscopic laser cycloablation. J Cataract Refract Surg 1999 Surg , 25:1214 Surg -1219 . This new approach to filtering procedure using a diode endoscopic laser was evaluated in a prospective, randomized study of 58 eyes in 58 patients. Twentynine eyes had phaco combined with trabeculectomy (14 with MMC, 15 without MMC) and 29 had phaco combined with endoscopic laser cycloablation. The study showed the laser procedure to be equally safe and efficient. 
